货号：AB9927

品牌：Merck Millipore

规格：

目录价：￥3475.00

市场价格：￥2953.75

会员价格：￥2780.00

金山科研平台，产品价格货期咨询微信：jinshanbio Description: Anti-phospho-Akt1 (Tyr326) Antibody | AB9927 View All» Replaces: 09-288 View All» Promotional Text: Special Shipping Offer on Antibodies100% Performance Guaranteed View All» Specificity: This antibody recognizes Akt1 phosphorylated at Tyr326. View All» Molecular Weight: ~56 kDa observed View All» Epitope: Phosphorylated Tyr326 View All» Immunogen: KLH-conjugated linear peptide corresponding to human Akt1 phosphorylated at Tyr326. View All» Modifications: Phosphorylation View All» Background Information: The serine/threonine kinase Akt family contains several members, including Akt1 (also designated PKB or RacPK), Akt2 (also designated PKB-β or RacPK-β) and Akt3 (also designated PKB-γ or thyoma viral proto-oncogene 3), which exhibit sequence homology with the protein kinase A and C families and are encoded by the c-Akt proto-oncogene. All members of the Akt family have a Pleckstrin homology domain. Akt1 and Akt2 are activated by PDGF stimulation. This activation is dependent on PDGFR-β tyrosine residues 740 and 751, which bind the 85 kDa subunit of the phosphatidylinositol 3-kinase (PI 3-kinase) complex. The activation of Akt1 and Akt2 is inhibited by the PI kinase inhibitor wortmannin. Taken together, this data strongly suggests that the protein signals downstream of the PI kinases. View All» Species Reactivity:

• Human

• Mouse

• Rat

• Canine

• Xenopus
  View All» Species Reactivity Note: Demonstrated to react with Human. Predicted to react with Mouse, Rat, Canine, and Xenopus based on 100% sequence homology. View All» Control: EGF treated and untreated HeLa cell lysates View All» Quality Assurance: Evaluated by Western Blot in EGF treated and untreated HeLa cell lysates.Western Blot Analysis: 2 µg/mL of this antibody detected AKT1 on 10 µg of EGF treated and untreated HeLa cell lysates. View All» Purification Method: Affinity purified View All» Presentation: Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. View All» Storage Conditions: Stable for 1 year at 2-8°C from date of receipt. View All» UniProt Number: P31749 View All» Entrez Gene Number: NP_001014431 View All» Gene Symbol:
  • AKT1

  • PKB

  • RAC
    View All» Alternate Names:
    • RAC-alpha serine/threonine-protein kinase

    • Protein kinase B

    • PKB

    • Proto-oncogene c-Akt

    • RAC-PK-alpha
      View All» Usage Statement: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. View All» Key Applications: Western Blotting View All» Entrez Gene Summary: The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq]. View All» UniProt Summary: FUNCTION: Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI3K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. Ref.6 Ref.10 Ref.14 Ref.15 Ref.17 Ref.19 CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein. ENZYME REGULATION: Three specific sites, one in the kinase domain (Thr-308) and the two other ones in the C-terminal regulatory region (Ser-473 and Tyr-474), need to be phosphorylated for its full activation. SUBUNIT STRUCTURE: Interacts with AGAP2 (isoform 2, PIKE-A), the interaction requires guanine nucleotides and stimulates the kinase activity. Interacts (via the C-terminus) with CCDC88A (via its C-terminus) and THEM4 (via its C-terminus). Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1A AND TCL1B. Interacts with TRAF6. Interacts with GRB10; the interaction leads to GRB10 phosphorylation thus promoting YWHAE binding. Interacts with RARA; the interaction phosphorylates RARA and represses its transactivation activity. Interacts with TNK2. SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane. Note: Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus. TISSUE SPECIFICTY: Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages. DOMAIN: Binding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI3K) results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.The AGC-kinase C-terminal mediates interaction with THEM4.PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells. Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome. Ref.10 Ref.14 Ref.17 Ref.34 Ref.8 Ref.20 Ref.9 Ref.16 Ref.21 Ref.26 Ref.27 INVOLVEMENT IN DISEASE: Defects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).SEQUENCE SIMILARITIES: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.Contains 1 AGC-kinase C-terminal domain.Contains 1 PH domain.Contains 1 protein kinase domain. View All» Product Name: Anti-phospho-Akt1 (Tyr326) View All» Concentration: 1 mg/mL View All» Antibody Type: Polyclonal Antibody View All» Qty/Pk: 100 μg View All» Format: Affinity Purified View All» Host: Rabbit View All»
      © 金山科研平台是专业的授权总代理区域代理经销平台。
      © 如需询价，请加客服QQ：1749072012 、客服微信：jinshanbio，或发送邮件到1749072012@qq.com
      © 平台为生命科学研究相关领域提供一站式耗材试剂仪器解决方案和采购服务，数据资源基于CC协议。
      © 本文地址：https://www.16ao.com/thread-158739.htm
      © Merck Millipore代理AB9927 Anti-phospho-Akt1 (Tyr326) (rabbit polyclonal)，产品报价联系微信jinshanbio